These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32248739)

  • 1. The prognostic values of systemic immune-inflammation index and derived neutrophil-lymphocyte ratio in EGFR-mutant advanced non-small cell lung cancer.
    Yucel S; Bilgin B
    J Oncol Pharm Pract; 2021 Jan; 27(1):71-77. PubMed ID: 32248739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy.
    Delikgoz Soykut E; Kemal Y; Karacin C; Karaoglanoglu O; Kurt M; Aytac Arslan S
    J Med Imaging Radiat Oncol; 2022 Feb; 66(1):146-157. PubMed ID: 34632714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
    Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
    J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs.
    Deng C; Zhang N; Wang Y; Jiang S; Lu M; Huang Y; Ma J; Hu C; Hou T
    Medicine (Baltimore); 2019 Aug; 98(33):e16875. PubMed ID: 31415428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer.
    Alessi JV; Ricciuti B; Alden SL; Bertram AA; Lin JJ; Sakhi M; Nishino M; Vaz VR; Lindsay J; Turner MM; Pfaff K; Sharma B; Felt KD; Rodig SJ; Gainor JF; Awad MM
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.
    Zhang Y; Chen Z; Jin F; Guo D; Chen Q; Liu Z; Ji S; Gao G
    Mediators Inflamm; 2021; 2021():2910892. PubMed ID: 34744510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer.
    Yan X; Li G
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32175568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil to Lymphocyte Ratio as a Prognostic Factor in European Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors.
    Aguiar-Bujanda D; Dueñas-Comino A; Saura-Grau S; Ros-Sanjuan L; Blanco-Sanchez MJ; Hernandez-Sosa M; Mori-De Santiago M; Galvan-Ruiz S; Lorenzo-Barreto JE; Vargas-Prado AM; Bohn-Sarmiento U
    Oncol Res Treat; 2018; 41(12):755-761. PubMed ID: 30419558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small cell lung cancer.
    Gao Y; Zhang H; Li Y; Wang D; Ma Y; Chen Q
    Clin Chim Acta; 2018 Sep; 484():272-277. PubMed ID: 29860033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.
    Zhang Y; Feng YC; Zhu HG; Xiong TC; Hou YS; Song J; Jiang W; Zhu CJ
    Medicine (Baltimore); 2018 Jul; 97(30):e11648. PubMed ID: 30045314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-radiotherapy systemic immune inflammation index associated with overall survival in patients with advanced EGFR mutant non-small cell lung cancer receiving thoracic radiotherapy.
    Chen D; Qin H; Deng G; Wang Q; Wang H; Liu X
    Clin Transl Oncol; 2023 Jan; 25(1):226-235. PubMed ID: 36070068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of systemic inflammatory markers with prognosis in erlotinib-treated EGFR-mutant non-small cell lung cancer.
    Yetişir AE; Paydaş S; Büyükşimşek M; Oğul A; Kolsuz İ; Kıdı MM
    J Cancer Res Ther; 2024 Jan; 20(1):285-288. PubMed ID: 38554335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of NLR, PLR, SII, and dNLR in Urothelial Bladder Cancer Following Radical Cystectomy.
    Salari A; Ghahari M; Bitaraf M; Fard ES; Haddad M; Momeni SA; Inanloo SH; Ghahari P; Mohamoud MM; Mohamadzadeh M; Nowroozi MR; Amini E
    Clin Genitourin Cancer; 2024 Oct; 22(5):102144. PubMed ID: 39032203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic changes in the systemic immune-inflammation index predict the prognosis of EGFR-mutant lung adenocarcinoma patients receiving brain metastasis radiotherapy.
    Wang Q; Tan X; Deng G; Fu S; Li J; Li Z
    BMC Pulm Med; 2022 Mar; 22(1):75. PubMed ID: 35241046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
    Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
    J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prognostic Value of a Derived Neutrophil-Lymphocyte Ratio in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Fan W; Zhang Y; Gao X; Liu Y; Shi F; Liu J; Sun L
    Clin Appl Thromb Hemost; 2021; 27():10760296211034579. PubMed ID: 34286626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis.
    Yang T; Hao L; Yang X; Luo C; Wang G; Lin Cai C; Qi S; Li Z
    BMJ Open; 2021 Sep; 11(9):e049123. PubMed ID: 34475167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer.
    Guo W; Cai S; Zhang F; Shao F; Zhang G; Zhou Y; Zhao L; Tan F; Gao S; He J
    Thorac Cancer; 2019 Apr; 10(4):761-768. PubMed ID: 30734516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics.
    Mezquita L; Preeshagul I; Auclin E; Saravia D; Hendriks L; Rizvi H; Park W; Nadal E; Martin-Romano P; Ruffinelli JC; Ponce S; Audigier-Valette C; Carnio S; Blanc-Durand F; Bironzo P; Tabbò F; Reale ML; Novello S; Hellmann MD; Sawan P; Girshman J; Plodkowski AJ; Zalcman G; Majem M; Charrier M; Naigeon M; Rossoni C; Mariniello A; Paz-Ares L; Dingemans AM; Planchard D; Cozic N; Cassard L; Lopes G; Chaput N; Arbour K; Besse B
    Eur J Cancer; 2021 Jul; 151():211-220. PubMed ID: 34022698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.